49
Participants
Start Date
October 31, 2016
Primary Completion Date
July 31, 2019
Study Completion Date
July 31, 2019
GC5107
GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
Lysosomal Rare Disorder Research and Treatment Center, Inc., Fairfax
Allergy Associates of Palm Beaches PA, North Palm Beach
Optimed Infusions LLC, Columbus
Midwest Immunology Clinic and Infusion Center, Plymouth
Oklahoma Institute of Allergy Ashma and Immunology, Oklahoma City
Pediatric Pulmonary Associates of North Texas, Frisco
Allergy Asthma and Immunology Clinic PA, Irving
Allergy Partners of North Texas Research, Dallas
Allergy and Asthma Specialists, Dallas
Immuno International Research Centers, Centennial
University of Alberta Hospital, Edmonton
Hamilton Health Sciences Corporation, Hamilton
Queen's University - Kingston General Hospital (KGH), Kingston
The Ottawa Hospital, Ottawa
Gordon Sussman Clinical Research, Toronto
Saint Michael's Hospital, Toronto
Hotel Dieu de Montreal, Montreal
CHU Ste-Justine - University of Montreal, Montreal
McGill University Health Centre (MUHC) - The Montreal Children's Hospital, Montreal
Clinique Spécialisée en Allergie de la Capitale, Québec
Lead Sponsor
Collaborators (2)
Parexel
INDUSTRY
Atlantic Research Group
OTHER
Green Cross Corporation
INDUSTRY